CA3126959A1 - Cancer treatment - Google Patents
Cancer treatment Download PDFInfo
- Publication number
- CA3126959A1 CA3126959A1 CA3126959A CA3126959A CA3126959A1 CA 3126959 A1 CA3126959 A1 CA 3126959A1 CA 3126959 A CA3126959 A CA 3126959A CA 3126959 A CA3126959 A CA 3126959A CA 3126959 A1 CA3126959 A1 CA 3126959A1
- Authority
- CA
- Canada
- Prior art keywords
- erdafitinib
- treatment
- cancer
- daily
- serum phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19156806 | 2019-02-12 | ||
| EP19156806.2 | 2019-02-12 | ||
| EP19176575 | 2019-05-24 | ||
| EP19176575.9 | 2019-05-24 | ||
| PCT/EP2020/053490 WO2020165181A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3126959A1 true CA3126959A1 (en) | 2020-08-20 |
Family
ID=69467563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3126959A Pending CA3126959A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168298A1 (https=) |
| EP (1) | EP3923942A1 (https=) |
| JP (2) | JP2022521173A (https=) |
| KR (1) | KR20210126654A (https=) |
| CN (1) | CN113423402A (https=) |
| AU (1) | AU2020223467B2 (https=) |
| BR (1) | BR112021015686A2 (https=) |
| CA (1) | CA3126959A1 (https=) |
| IL (1) | IL285466A (https=) |
| JO (1) | JOP20210216A1 (https=) |
| MA (1) | MA54932A (https=) |
| MX (1) | MX2021009670A (https=) |
| PH (1) | PH12021551949A1 (https=) |
| SG (1) | SG11202107850VA (https=) |
| TW (1) | TWI863962B (https=) |
| WO (1) | WO2020165181A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN112957368A (zh) * | 2021-04-02 | 2021-06-15 | 南昌大学 | 一种司维拉姆的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4063516A1 (en) * | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| AU2016341445B2 (en) * | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-02-11 PH PH1/2021/551949A patent/PH12021551949A1/en unknown
- 2020-02-11 WO PCT/EP2020/053490 patent/WO2020165181A1/en not_active Ceased
- 2020-02-11 KR KR1020217028671A patent/KR20210126654A/ko not_active Ceased
- 2020-02-11 CN CN202080013784.5A patent/CN113423402A/zh active Pending
- 2020-02-11 MA MA054932A patent/MA54932A/fr unknown
- 2020-02-11 BR BR112021015686-0A patent/BR112021015686A2/pt unknown
- 2020-02-11 EP EP20703477.8A patent/EP3923942A1/en active Pending
- 2020-02-11 SG SG11202107850VA patent/SG11202107850VA/en unknown
- 2020-02-11 JO JOP/2021/0216A patent/JOP20210216A1/ar unknown
- 2020-02-11 US US17/430,025 patent/US20220168298A1/en active Pending
- 2020-02-11 AU AU2020223467A patent/AU2020223467B2/en active Active
- 2020-02-11 JP JP2021547154A patent/JP2022521173A/ja not_active Withdrawn
- 2020-02-11 CA CA3126959A patent/CA3126959A1/en active Pending
- 2020-02-11 MX MX2021009670A patent/MX2021009670A/es unknown
- 2020-02-12 TW TW109104389A patent/TWI863962B/zh active
-
2021
- 2021-08-09 IL IL285466A patent/IL285466A/en unknown
-
2025
- 2025-09-29 JP JP2025162216A patent/JP2026016402A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521173A (ja) | 2022-04-06 |
| EP3923942A1 (en) | 2021-12-22 |
| PH12021551949A1 (en) | 2022-07-18 |
| AU2020223467B2 (en) | 2025-12-04 |
| KR20210126654A (ko) | 2021-10-20 |
| SG11202107850VA (en) | 2021-08-30 |
| MX2021009670A (es) | 2021-09-08 |
| JOP20210216A1 (ar) | 2023-01-30 |
| CN113423402A (zh) | 2021-09-21 |
| AU2020223467A1 (en) | 2021-08-05 |
| TW202045173A (zh) | 2020-12-16 |
| JP2026016402A (ja) | 2026-02-03 |
| MA54932A (fr) | 2021-12-22 |
| TWI863962B (zh) | 2024-12-01 |
| IL285466A (en) | 2021-09-30 |
| WO2020165181A1 (en) | 2020-08-20 |
| BR112021015686A2 (pt) | 2021-10-26 |
| US20220168298A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201871B2 (en) | Cancer treatment | |
| WO2018141921A1 (en) | Cancer treatment | |
| AU2018278271A1 (en) | FGFR2 inhibitors for the treatment of cholangiocarcinoma | |
| AU2020223467B2 (en) | Cancer treatment | |
| HK40103983A (en) | Cancer treatment | |
| HK40018978A (en) | Cancer treatment | |
| HK40018978B (en) | Cancer treatment | |
| WO2020205493A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EA052711B1 (ru) | Лечение рака | |
| EA051616B1 (ru) | Лечение рака | |
| HK40013982A (en) | Cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241007 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250212 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250626 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251027 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260105 |